Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (98)	12/24/1997 12:15:00 PM
From: Michael C. Woodward	Respond to of 534

Geewiz, nice talking to you. I have seen you on a few other threads that I follow. I believe that the prospects for price appreciation of BJCT stock won't happen until mid-98. We should have news on how the glucose monitoring system is going by then. I think that there is no question that the overall market, especially high tech, biotech and medical has been hit hard. No major news has come out with Bioject, so a lot of traders who bought BJCT in the .50 - .75 range have been taking profits. Volume has been consistently low. I agree on your trading range except that I think (hope) that the bottom is $1.00. But I haven't been right very often since those two miserable days last October. I am loaded up and can't buy anymore. My professional background has been 30 years in high technology financial management (mostly Silicon Valley). I got out of the rat race in 1992 and moved to Central Oregon to play golf and do consulting. Recently I invested in a medical software start-up. I plan to help them develop a business plan and get funding for their first test site. Other than that, I plan to lower my golf handicap, but in Central Oregon you don't play much golf December through February.I also spend time on SI, but the only thing I have enjoyed for awhile has been the joke string. WHY I AM BULLISH ON BIOJECT: 1. James O'Shea (CEO) has a proven track record and will add considerable value to shareholders. 2. Bioject has a solid BOD (Elan's VP Planning, Michael Sember, Rick Plestina (I know him), and another member who has solid credentials in the medical field (David deWeese). 3. I am a small player in a partnership (20M+) that has spent a lot of time with the management team at Bioject and they are certain that this stock will move by 1st quarter 1998. The partnership has warrants. My managers have an excellent track record (don't miss many). 4. Bioject's base business is solid. 5. The Special Meeting of Shareholders, scheduled for 12/9/97 was cancelled. It is my understanding that they have rescheduled this meeting to January. I made a call today to confirm the date and won't know until Thursday the 29th of December. Bioject's entry into the field of glucose monitoring for diabetics should be an excellent growth opportunity. They are approaching this venture with Elan in a very positive manner. (1) conversion of a $12 Million promissory note to Preferred Stock, freeing up cash for the development of glucose monitoring system. 6. Strong relationship with Elan. 7. 37.8% of stock held by following: Elan 4,477,273 16.6% Hambrecht & Quist 3,380,300 12.8% Paramount Capital 2,239,842 8.4% I like H&Q.